First published November 8, 2023 by Industry Today
Read the full article
North America is expected to hold the largest market share due to the presence of women who experience menopausal symptoms increasing actively in the US.
Menopausal hot flashes are the most common symptoms observed in 50-55 years women during menopause. It is caused by hormone fluctuation, especially estrogen; heart palpitations and dizziness can accompany this symptom. Hormone-infused drugs are used to treat hot flashes, which is preferred mostly.
According to John Hopkin's Medicine, 2023, About 75% of all women have these sudden, brief, periodic increases in their body temperature. Usually, hot flashes start before a woman's last period. For 80% of women, hot flashes occur for two years or less. The treatment includes hormonal therapy, antidepressants, etc. However, estrogen therapy is the most effective treatment for relieving menopausal hot flashes.
Market Dynamics: Drivers & Restraints
Increasing menopausal women
Menopause is one of the most common conditions every woman has to go through once in life. The symptoms vary in individuals, such as hot flashes, night sweats, pain during sexual intercourse, mood swings, etc. It occurs at 50-55 in most women: the U.S. census data more than 15 million women ages 45 to 60 in the workplace. An increase in number of menopausal women worldwide is observed according to the data provided.
Menopause occurs at a median age of 51.3 years in the United States. National Institute of Health, in 2023, stated that nearly 80% of women worldwide suffer from vasomotor symptoms (VMS) that can range in severity and affect quality of life and overall health.
According to Mayo Clinic, 2022, By 2030, the world population of menopausal and postmenopausal women is projected to increase to 1.2 billion, with 47 million new entrants each year.
Furthermore, increase in expenditure of women in menopause care, increase in awareness among women, rising advancements in drug discoveries are few factors that are expected to drive the market in the forthcoming period.
Side effects of Hormonal drugs
Side effects of hormone therapy include an increased risk of endometrial cancer with long-term use. Increased risk of blood clots and stroke are observed. If the hormone therapy was started at early stages due to early menopause, there is an increased chance of dementia in women. Gallstones and gallstone problems are also common if the medication is continued for a long time.
Market Segment Analysis
The Global menopausal hot flashes are segmented based on treatment, route of administration, distribution channel and region.
The Hormone therapy segment accounted for approximately 43.1% of the market share.
Hormone therapy is expected to hold the largest share of the market. For instance, the imbalance of hormones like estrogen is the main reason for menopausal symptoms. A decrease in the level of hormones shows extreme symptoms (hot flashes, night sweats). A few healthcare startups launched hormonal supplements to combat the hot flashes in most women.
For instance, in August 2023, Rebalance Health, a startup, launched lozenges to help rebalance hormones in menopausal women who experience symptoms like hot flashes, night sweats, etc.
Furthermore, in May 2022, Hologram Sciences launched Phenology, a beauty and wellness brand with curated nutritional supplements to lower the symptoms of menopause, such as hot flashes, night sweats, mood swings, etc.
In April 2023, pH-D Feminine Health launched a new line of oral supplements to support women's menopausal health.
North America accounted for approximately 40.2% of the market share in 2022
North America is expected to hold the largest market share due to the presence of women who experience menopausal symptoms increasing actively in the US. For instance, according to Cuyuna Regional Medical Organisation, in 2022, sixty-four million US women are 50 and older who are at menopausal age.
The cost of menopausal care is also increasing in the US because more working women are present in the US who are older than 45. For instance, according to The New York Times, 2023, Menopause costs American women an estimated $1.8 billion in lost working time per year.
According to the North American Menopause Society, 2023 By 2025, the number of postmenopausal women is expected to rise to 1.1 billion worldwide.